5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.84▼ | 3.90▼ | 3.93▼ | 4.10▼ | 4.45▼ |
MA10 | 3.85▼ | 3.96▼ | 3.99▼ | 4.25▼ | 4.87▼ |
MA20 | 3.89▼ | 4.01▼ | 4.05▼ | 4.52▼ | 5.98▼ |
MA50 | 3.96▼ | 4.11▼ | 4.20▼ | 4.99▼ | 6.97▼ |
MA100 | 4.01▼ | 4.22▼ | 4.40▼ | 6.12▼ | 8.54▼ |
MA200 | 4.07▼ | 4.45▼ | 4.73▼ | 6.66▼ | 10.30▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.005▼ | -0.017▼ | -0.019▼ | -0.041▼ | -0.146▼ |
RSI | 23.343▼ | 19.690▼ | 22.948▼ | 28.747▼ | 32.220▼ |
STOCH | 24.502 | 10.448▼ | 14.503▼ | 13.720▼ | 9.019▼ |
WILL %R | -92.857▼ | -96.429▼ | -97.561▼ | -99.225▼ | -99.678▼ |
CCI | -141.462▼ | -200.254▼ | -201.189▼ | -167.159▼ | -158.681▼ |
Thursday, April 18, 2024 09:00 AM
LendingClub Corp. engages in an online marketplace that facilitates loans to borrowers and investments. It operates through the LendingClub Bank and LendingClub Corporation (Parent Only) segments ...
|
Thursday, April 18, 2024 02:03 AM
NEW YORK, NY / ACCESSWIRE / April 18, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to ...
|
Tuesday, April 16, 2024 06:35 PM
CASE DETAILS: The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
18/04/24 | 4.05 | 4.08 | 3.79 | 3.80 | 1,659,800 |
17/04/24 | 4.20 | 4.2005 | 4.02 | 4.07 | 1,337,487 |
16/04/24 | 4.15 | 4.19 | 4.06 | 4.12 | 1,252,081 |
15/04/24 | 4.31 | 4.3644 | 4.175 | 4.23 | 1,089,915 |
12/04/24 | 4.41 | 4.4662 | 4.16 | 4.295 | 1,127,643 |
11/04/24 | 4.30 | 4.50 | 4.30 | 4.45 | 803,845 |
10/04/24 | 4.23 | 4.295 | 4.17 | 4.29 | 1,411,559 |
09/04/24 | 4.40 | 4.445 | 4.29 | 4.39 | 975,661 |
08/04/24 | 4.45 | 4.51 | 4.34 | 4.39 | 862,071 |
05/04/24 | 4.45 | 4.52 | 4.34 | 4.42 | 1,115,978 |
|
|
||||
|
|
||||
|
|